Ironwood Starts Phase I Trial of Anti-Anxiety Drug in US
December 21, 2012 at 06:36 AM EST
Bionomics Limited has been advised by its licensee Ironwood Pharmaceuticals (NASDAQ: IRWD ) that, following the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) last month, the planned Phase I clinical trial of the investigational anti-anxiety drug candidate IW-2143 (BNC210) has
